Your session is about to expire
← Back to Search
Microbial Ecosystem Therapeutic
MET-2 20 g for Anxiety
Phase 2
Waitlist Available
Led By Roumen Milev, MD/PhD
Research Sponsored by NuBiyota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Able to provide informed consent.
Not pregnant
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline vs. week 6
Awards & highlights
Study Summary
To measure the effects of Microbial Ecosystem Therapeutics (MET)-2 on symptoms of depression and anxiety using pre- and post-treatment scores for overall depression and anxiety
Eligible Conditions
- Depression
- Anxiety
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline vs. week 6
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline vs. week 6
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in Anxiety Symptoms
Mental Depression
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: MET-2 20 gExperimental Treatment1 Intervention
Loading dose of MET-2 is administered for the first two days, followed by a regular, daily dose for the duration of the study (6 weeks total).The loading dose will consist of 5 g of MET-2 in the form of ten capsules orally on day one and on day two. The regular daily dose will consist of 1.5 g MET-2 in the form of three MET-2 capsules taken once daily, excluding days where they take the booster (same as loading dose).
Group II: PlaceboPlacebo Group1 Intervention
Loading dose of placebo is administered for the first two days, followed by a regular, daily dose of placebo for the duration of the study (6 weeks total).The loading dose will consist of ten capsules of placebo (which match the MET-2 capsules in appearance and weight) taken orally on day one and on day two. The regular daily dose will consist of three placebo capsules taken once daily, excluding days where they take the booster (same as loading dose).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MET-2
2017
Completed Phase 1
~70
Find a Location
Who is running the clinical trial?
NuBiyotaLead Sponsor
8 Previous Clinical Trials
181 Total Patients Enrolled
Roumen Milev, MD/PhDPrincipal InvestigatorQueens University
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger